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ABSTRACT
Background: Schistosomiasis is a
major public health problem in developing countries. Currently, praziquantel (PZQ) is the drug of choice
for human schistosomiasis. Isosorbide-5-mononitrate (IS-5-MN) is a nitro compound that is used as an antianginal remedy. It must be
enzymatically metabolized to release
nitric oxide (NO) to exert its pharmacologic activities. This study evaluates the vasodilator effect of the
NO donor IS-5-MN on hepatic bilharzial lesions caused by Schistosoma
mansoni, and determines whether
the combined use of IS-5-MN and
PZQ is synergistic or antagonistic.

Methods: Swiss albino female
mice (CD I strain) were divided into
five groups: (i) non-infected; (ii) infected non-treated; (iii) infected and
treated with PZQ, 6 weeks post infection (WPI) in a dose of 500 mg/
kg/day for two successive days; (iv)
infected and treated with IS-5-MN
from the fourth to the tength WPI 5
days/week in a dose of 10.08 mg/kg;
(v) infected and treated with IS-5-MN
as group (iv) in addition to PZQ as
group (iii). Parasitological, biochemical and histopathological parameters
that assess disease severity and
morbidity were investigated.
Results:

PZQ

significantly

in-
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creased the percentage of dead
eggs, decreased granuloma number
but did not reduce granuloma diameter. IS-5-MN administered alone did
not induce a shift in the oogram pattern, but it reduced inflammation, necrosis and granuloma diameter. The
simultaneous administration of both
drugs significantly increased NO level in liver homogenates and induced
modulation of granuloma size. The
best results were obtained in the
mice group treated with IS-5-MN in
addition to PZQ.
Conclusions: Our results point to
IS-5-MN as a promising medication
that could be used as a combined
therapy with PZQ to ameliorate
schistosomal liver pathology. Further
studies are recommended to explore
effects of IS-5-MN and PZQ coadministration in schistosomiasis advanced liver fibrosis.
Keywords: Schistosoma mansoni,
liver
fibrosis,
isosorbide-5mononitrate, praziquantel, nitric oxide, granuloma.

INTRODUCTION
Schistosomiasis is a tropical parasitic disease caused by genus
Schistosoma [1]. In spite of the hard

control efforts, schistosomiasis remains a major health problem that
ranks with malaria and tuberculosis
as a major source of morbidity affecting almost 240 million people worldwide [2].
The main lesions in chronic infection are caused by a complex
delayed-type hypersensitivity response to sequestered viable, dying or dead ova that are trapped in
the tissues. The eggs secrete proteolytic enzymes that induce eosinophilic inflammatory and granulomatous
reactions,
which
are
progressively replaced by fibrous
tissue [3].
Schistosomal liver fibrosis results
from an intense accumulation of collagen fibrils in the periportal spaces,
leading to pathognomonic periportal
or Symmer's pipestem fibrosis with
its consequences e.g. portal hypertension, splenomegaly, collateral venous circulation, portocaval shunting, and gastrointestinal varices [4].
Liver fibrosis is initiated by hepatic
injury; hepatocyte damage releases
cytokines such as transforming
growth factor-α (TGF-α), and tumor
necrosis factor-α (TNF α) [5]. In turn,
the principle masters of liver fibrosis
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i.e. hepatic stellate cells (HSCs) are
stimulated [6] and transform into
myofibroblasts [7].
Nitric oxide deficiency had been
linked to liver fibrosis [8]. NO can
induce apoptosis of activated HSC
and inhibit their proliferation, motility,
and
contractility in addition
to
reducing excessive extracellular matrix (ECM) in fibrotic liver [9]. Besides, it impairs the release of inflammatory mediators [10], improves
intrahepatic vascular response to
portal blood flow [11] and leads to
suppression of pro-inflammatory cytokines such as interferon-α (IFN-α)
and TNF-α [12]. Consequently, NO
donors can exert an anti-fibrotic action as documented in previous studies [13]. IS-5-MN is the most commonly used long-acting NO donor
and one of the most frequently used
drugs in the treatment of coronary
artery disease characterised by well
tolerance and lack of serious side effects [14].
Thus, the aim of this study was to
evaluate the effect of the NO donor
IS-5-MN on hepatic lesions caused
by S. mansoni and to determine the
effect of PZQ and IS-5-MN coadministration.

MATERIAL & METHODS
I. Animals, parasites and infection
All
animal studies were approved by the Medical Experimental Research Center (MERC),
Faculty of Medicine, Mansoura University, Mansoura, Egypt,
based
on the institutional and national regulations for animal experimentation.
A total of 67 Swiss albino female
mice of CD I strain (aged 6-8 weeks,
and weighting 20-25 gm) were purchased from the Schistosome Biological Supply center (SBSC), Theodor

Bilharz

Research

Institute

(TBRI), Imbaba (Giza), Egypt. Mice
were infected with S. mansoni cercariae Egyptian strain, freshly shed
from infected Biomphalaria alexandrina snails, purchased from the
SBSC, TBRI, after exposure to light
for 30 minutes. Each mouse was
subcutaneously infected with 60 ± 10
cercariae [15].
Mice

were

kept

in

an

air-

conditioned animal house (MERC) at
20–22 °C, with 12 h light and 12 h
dark cycle, and maintained on a
standard commercial pellet diet, normal drinking water ad libitum.
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II. Drugs and treatment regimens
Isosorbide-5-mononitrate (Effox,
Minapharm, Egypt), and praziquantel
(Biltricide, Alexandria Co. for Pharmaceuticals & Chemical Industries,
Egypt) were used in the study. The
dose of IS-5-MN used for mice was
equivalent
to the highest dose,
which induced improvement in rat
model of carbon tetrachloride
(CCl4)-induced liver injury [13]. According to Paget and Barnes [16]
drug conversion tables, IS-5-MN
dose used for mice was calculated to
be 10.08 mg/kg. It was administered
from the fourth to the tength WPI, 5
days/week. PZQ was ground and
used as a freshly prepared aqueous
suspension in 2% Cremophor El
(Sigma Chemical Co., St. Louis, MO,
USA), and was given 6 WPI in a
dose of 500 mg/kg/day for two successive days [17]. Drugs were administered by oral gavage using a
mouse feeding needle (Kent Scientific Corporation), in a volume of 200
µl/mouse.
III. Animal groups
Mice were randomly allocated
into five groups, each of 10-15 mice
at the beginning of the experiment:
-

Group I: normal, non-infected
(n= 10).

-

Group II: infected non-treated
(n= 14).

-

Group III: infected and treated
with PZQ (n= 13).

-

Group IV: infected and treated
with IS-5-MN (n= 15).

-

Group V: infected and treated
with IS-5-MN and PZQ (n= 15).
Mice in all groups were euthanized at the end of the study,
10 WPI.

IV. Parasitological study
After euthanasia, the peritoneal
cavity was opened to obtain fragments from the small intestine and
the percentages of the different egg
developmental stages (oogram pattern) were examined [18].
V. Biochemical study on liver homogenates
Nitric oxide level was assessed in
liver homogenates using a commercially available kit (Catalogue number NO 25 32, Biodiagnostics, Dokki,
Giza, Egypt).
VI. Histopathological studies
Liver portions from euthanized
mice were fixed in 10% neutral buffered formalin, and processed to paraffin blocks. Sections were cut 5 µm
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thick, and then stained with haematoxylin and Eosin (H&E) to evaluate
histopathological changes. Lobular
inflammation was graded [19] from
0–3 based on inflammatory foci per
200* magnification (0 = none; 1 =
1–2/200*; 2 = up to 4/200*; 3 = >4/
200*). Focal necrosis in liver cells
around the central vein away from
granuloma was scored [20] as follows: none (0%); minimal (1–10%);
mild (11–30%); moderate (31–60%);
and marked (> 60% of liver cells
were affected). Inflammatory cellular
infiltrate [21] was evaluated in five
microscopic fields of highest inflammatory intensity at 40x magnification
and graded as follows: minimal (≥
25% inflammatory cells); mild
(26–50%); moderate (51–75%); and
marked (> 75%).

Statistical analysis
Data were analyzed using statistical package for social sciences
(SPSS) software (SPSS Inc., Chicago, IL, USA), version 21. Continuous
variables were presented as mean ±
standard deviation (SD) for parametric data, and median for nonparametric data. Analysis of variance
(ANOVA) followed by Tukey's test
were used to compare means of
more than 2 groups (parametric

139

data), while Kruskal Wallis (KW) test
was used to compare the median of
more than two groups (nonparametric data). Comparison between categorical variables was carried out using Chi-square test. The
results were considered significant
when the probability of error is equal
to or less than 5% (p ≤ 0.05), and
highly significant when the probability of error is equal to or less than
0.1% (p ≤ 0.001).

RESULTS
I. Parasitological study
Treatment of mice with PZQ 6
WPI significantly decreased (P ≤
0.01) the percentage of mature
eggs, caused complete absence of
immature eggs and significantly increased (P 0.000) the percentage of
dead eggs. IS-5-MN administered in
a dose of 10.08 mg/kg for 5 weeks
starting from the 4th to the 10th WPI
5 days/week caused no reduction in
the percentage of dead eggs, no reduction in the percentage of immature eggs and did not increase the
percentage of dead eggs. Combined
administration of IS-5-MN and PZQ
induced complete absence of immature eggs and significantly increased
(P < 0.05) the percentage of dead
eggs (Table 1).
MANSOURA MEDICAL JOURNAL
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II. Biochemical study on liver homogenates
Nitric oxide assay
Infection of mice with S. mansoni
significantly decreased (P < 0.05)
NO level (Table 2), in comparison
with non-infected group. Combined
administration of IS-5-MN and PZQ
significantly increased (P= 0.000)
NO level by 289.47%, when compared to infected non-treated mice.
III. Histopathological studies
Histopathological examination of
the liver sections from infected nontreated mice showed preserved architecture, moderate inflammation of
liver parenchyma, moderate focal
necrosis, moderate inflammatory cell
infiltrate, and a large number (Figure
1A) of irregularly outlined granuloma
(Figure2A).
Administration of PZQ 6 WPI

caused no amelioration of the parenchymatous changes, when compared to infected non-treated group.
However, it decreased the number of
granuloma (Figure 1B) but did not
reduce their size (Figure2B).
On the other hand, IS-5-MN led to
significant amelioration of the parenchymatous changes. Liver sections
exhibited mild inflammation of liver
parenchyma, mild focal necrosis, significantly diminished inflammatory
cell infiltrate, evident granuloma circumscription, and reduced granuloma diameter (Figure 2C), when
compared to infected non-treated
mice.
In addition, the combined administration of IS-5-MN and PZQ significantly diminished inflammatory cell
infiltrate and reduced granuloma
count and diameter (Figure2D).
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Figure (1): Histopathological study of liver sections of Schistosoma mansoni-infected
mice euthanized 10 weeks post infection (H&E *40). (A) Section from infected non-treated mice group showing large number of granuloma with irregular outline. Arrows point to eggs in granuloma. (B) Section from mice
treated with PZQ (500 mg/kg/day 6 WPI for 2 successive days) showing
small number of large sized granuloma with no eggs in the center. Arrows
point to granuloma.
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Figure (2): Histopathological study of liver sections of Schistosoma mansoni-infected
mice euthanized 10 weeks post infection (H&E *100). (A) Section from infected non-treated mice group showing large sized granuloma with irregular
outline. Arrow points to egg in granuloma. (B) Section from mice treated
with PZQ (500 mg/kg/day 6 WPI for 2 successive days) showing large
sized granuloma with irregular outline. Arrow points to granuloma. (C) Section from mice treated with IS-5-MN showing small sized concised granuloma and reduced inflammatory cell infiltrate. Arrow points to egg in granuloma. (D) Section from mice treated with IS-5-MN and PZQ showing small
sized concised granuloma. Arrow points to egg in granuloma.
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DISCUSSION
Schistosomiasis affects about
240 million people worldwide and is
considered the most frequent cause
of liver fibrosis [2]. In schistosomiasis, liver damage takes place 5 WPI,
coincident with the onset of oviposition. Eggs that are trapped within the
liver provoke a chronic granulomatous inflammatory response [22]. Inflammation and fibrosis accompanied with vascular changes underlie
liver pathology in schistosomiasis
from the very early scattered periovular granulomas to the advanced
periportal fibrosis with its sequelae
[23]. It is worth noting that antischistosomal drugs successfully
eradicate adult parasites with minimal improvement in liver pathology
that is related to parasitological cure
[24]. So, other medications that can
target the scarring process are urgently needed to prevent progression to irreversible cirrhosis [25].
Progressive liver fibrosis is principally maintained by chronic activation of the wound healing response
and oxidative stress [26]. Among the
most commonly used NO donors, organic nitrates as IS-5-MN is widely
used as long acting anti-ischaemic
vasodilator drug. Vasodilator proper-

ties of IS-5-MN are mediated
through NO release [27]. In turn, NO
is involved in each stage of wound
healing process through modulating
inflammation, angiogenesis, cell proliferation, matrix deposition, and remodeling [28]. In addition to the documented anti-microbial properties of
NO [29], the drug can be tested in liver fibrosis model of schistosomiasis
both as anti-fibrotic and as antischistosomal drug.
To our knowledge, this is the first
study evaluating the effects of the
NO donor IS-5-MN on an experimental model of S. mansoni.
In the current study, IS-5-MN administered alone did not cause significant alterations in the oogram pattern, indicating that the drug does
not have anti-schistosomal activity;
(Table 1), since alteration in the oogram pattern is one of the most important parameters expressing the
activity of anti-schistosomal drugs
[18].
Nitric oxide can have a cytoprotective or cytotoxic effect. This depends on the initial injury, the
source, rate of production, the balance between NO and other inflam-

Vol. 43, No. 1 & 2 Jan. & April, 2014

https://mmj.mans.edu.eg/home/vol43/iss2/1
DOI: 10.21608/mjmu.2014.124753

10

Alhusseiny et al.: THE HEPATOPROTECTIVE EFFECT OF NITRIC OXIDE ON MURINE SCHISTOSOMI

Samar M. Alhusseiny et al...
matory cytokines and mediators e.g.
TNF-α, IL-1β, IFN-γ and reactive oxygen species (ROS), and concentration in the tissues [30]. NO exerts a
protective role under oxidative stress
resulting from ROS. It was documented that only microM levels of
NO are required to protect against
these ROS [31].
Administration of IS-5-MN alone
did not increase NO level because
the drug did not possess antischistosomal activity, resulting in
persistent state of oxidative stress.
On the other hand, PZQ exerted
anti-schistosomal effect but did not
significantly alter inflammation and
necrosis. Combined administration
of IS-5-MN and PZQ induced a synergistic effect and significantly increased NO level, in comparison
with infected non-treated group, because of the combination of antischistosomal activity of PZQ and the
hepatoprotective effect of NO donation caused by IS-5-MN (Table 2).
Significant amelioration of the parenchymatous changes in IS-5-MN
administered group could be visualized in the context of antiinflammatory properties of NO. Other
anti-inflammatory drugs were tested

145

in previous studies e.g. El-Lakkany
et al. [32] who reported the effect of
silymarin as an anti-inflammatory
and anti-fibrotic agent alone and in
combination with PZQ on schistosomiasis mansoni-infected mice.
Co-administration of PZQ and IS5-MN diminished granuloma number
and size, when compared to infected
non-treated mice. Our results run in
parallel with those recorded by Abdel-Hafeez et al. [33], who documented reduced granuloma number, in response to PZQ only, and diminished
size and number following combined
alpha lipoic acid and PZQ therapy.
Also, similar findings were published
by Wang et al. [34], who investigated
the effect of vitamin E administration
in S. japonicum-infected mice, and
documented improvement of liver pathology following vitamin E supply,
and reduced granuloma count and
size.
Our results are in line with previous studies using another NO donor
drug
S-Nitroso-N-acetylcysteine
(SNAC) as an effective anti-fibrotic
agent in Sprague-Dawley rats [35].
Also, in another study, sodium nitroprusside; one of NO donors in combination with mesenchymal stem cell
MANSOURA MEDICAL JOURNAL
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(MSC) transplantation increased
MSC ability to repair fibrotic liver
as a consequence of NO induced
HSC apoptosis [36]. Results
of
the present study reinforce results
of a previous study from Egypt
showing marked reduction of CCl4
induced liver fibrosis after treatment
with IS-5-MN alone or in combination with the anti-oxidant silymarin
[13].
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ا ﻠﺨــﺺ اﻟﻌﺮﺑــﻰ
اﻟﺘﺄﺛﻴﺮ اﻟﻮاﻗﻲ ﻷﻛﺴﻴﺪ اﻟﻨﻴﺘﺮﻳﻚ ﻟﻠﻜﺒﺪ ﻓﻲ اﻟﺒﻠﻬﺎرﺳﻴﺎ
ا ﻌﻮﻳﺔ اﻟﺘﺠﺮﻳﺒﻴﺔ ﻓﻲ اﻟﻔﺌﺮان
م.م .ﺳﻤﺮ اﳊﺴﻴﻨﻲ*
أ.د /ﻣﻬﺎ أﺑﻮ ﻫﺎﺷﻢ **
د /ﻋﺒﻴﺮ اﳊﻨﺎوى *

أ.د /ﺳﻤﺮ اﻟﺒﺸﺒﻴﺸﻲ*
أ.د /ﺣﺴﺎم اﻟﺪﻳﻦ اﻟﻨﻤﺮ*
أ.د /آﻳﺔ ﺣﻨﺪوﺳﺔ*

ﻣﻦ ﻗﺴﻤﻰ اﻟﻄﻔﻴﻠﻴﺎت اﻟﻄﺒﻴﺔ واﻟﺒﺎﺛﻮﻟﻮﺟﻰ**  -ﻛﻠﻴﺔ اﻟﻄﺐ  -ﺟﺎﻣﻌﺔ ا ﻨﺼﻮرة.
ﺗُﻌَـﺪ اﻟﺒـﻠﻬـﺎرﺳﻴﺎ ﻣـﺸﻜـﻠﺔ ﺻـﺤﺔ ﻋﺎﻣـﺔ رﺋﻴـﺴﻴـﺔ ﻓﻲ اﻟﺪول اﻟـﻨﺎﻣﻴـﺔ و ﻳُﻌـﺘﺒـﺮ اﻟﺒﺮازﻳـﻜﻮاﻧـﺘﻴﻞ ﺣـﺎﻟﻴ ًﺎ
اﻻﺧﺘـﻴﺎر اﻷﻣﺜﻞ ﻟـﻌﻼج اﻟﺒﻠﻬـﺎرﺳﻴﺎ ﻓﻲ اﻹﻧـﺴﺎن و ﻳُﻌَﺪ اﻷﻳـﺰوﺳﻮرﺑﻴـﺪ -٥-أﺣﺎدي اﻟﻨﺘـﺮات ﻣﻦ ا ﺮﻛﺒﺎت
اﻟﺘـﻲ ﲢﺘـﻮي ﻋـﻠﻰ اﻟـﻨـﻴـﺘـﺮوﺟ و اﻷﻛـﺴـﺠـ و ﻳـﺘﻢ ﺗـﺄﻳـﻴـﻀﻪ ﻋﻦ ﻃـﺮﻳﻖ اﻻﻧـﺰ ﺎت ﻟـﺘـﺤـﺮﻳـﺮ أﻛـﺴـﻴﺪ
اﻟﻨﻴﺘﺮﻳﻚ ﻟﻴﻘﻮم ﺑﺘﺄﺛﻴﺮاﺗﻪ اﻟﺪواﺋﻴﺔ.
و ﺗُـﻘَـﻴﻢ ﻫـﺬه اﻟـﺪراﺳـﺔ ﺗﺄﺛـﻴـﺮ ﻣـﺎﻧﺢ أﻛـﺴـﻴـﺪ اﻟﻨـﻴـﺘـﺮﻳﻚ اﻷﻳـﺰوﺳـﻮرﺑﻴـﺪ -٥ -أﺣـﺎدي اﻟـﻨـﺘـﺮات ا ُﻮَﺳِّﻊ
ﻟﻸوﻋﻴـﺔ اﻟﺪﻣﻮﻳـﺔ ﻋﻠﻰ اﻟـﺒﻠـﻬﺎرﺳـﻴﺎ اﻟﻜـﺒﺪﻳـﺔ و ﺗُﺤَـﺪد ﻣﺎ إذا ﻛـﺎن اﺳﺘﻌـﻤﺎل اﻷﻳـﺰوﺳﻮرﺑـﻴﺪ  -٥ -أﺣﺎدي
اﻟﻨﺘﺮات ﻣﻊ اﻟﺒﺮازﻳﻜﻮاﻧﺘﻴﻞ ﻣُﺆَازِراً )ﻣُﻘﻮﻳﺎً( أو ﻣُﻀَﺎدﱠاً.
و ﻗﺪ

ﺗﻘﺴﻴﻢ إﻧﺎث اﻟﻔﺌﺮان اﻟﺒﻴﻀﺎء إﻟﻰ ﺧﻤﺲ ﻣﺠﻤﻮﻋﺎت:

 ﻣﺠﻤﻮﻋﺔ  :١ﻓﺌﺮان ﻏﻴﺮ ﻣﺼﺎﺑﺔ )ﻣﺠﻤﻮﻋﺔ ﺿﺎﺑﻄﺔ(. ﻣﺠﻤﻮﻋﺔ  :٢ﻓﺌﺮان ﻣﺼﺎﺑﺔ ﺑﺎﻟﺒﻠﻬﺎرﺳﻴﺎ ا ﻌﻮﻳﺔ )ﻣﺼﺎﺑﺔ ﻏﻴﺮ ﻣﻌﺎﳉﺔ(. ﻣﺠﻤﻮﻋﺔ  :٣ﻓﺌﺮان ﻣﺼﺎﺑﺔ و ﺗﻤﺖ ﻣﻌﺎﳉﺘﻬﺎ ﺑﺎﻟﺒﺮازﻳﻜﻮاﻧﺘﻴﻞ ﺑﻌﺪ  ٦أﺳﺎﺑﻴﻊ ﻣﻦ اﻟﻌﺪوى. ﻣﺠـﻤﻮﻋﺔ  :٤ﻓـﺌﺮان ﻣـﺼﺎﺑﺔ و ﺗـﻤﺖ ﻣﻌـﺎﳉﺘﻬـﺎ ﺑﺎﻷﻳـﺰوﺳﻮرﺑـﻴﺪ -٥-أﺣﺎدي اﻟـﻨﺘـﺮات ﻣﻦ اﻷﺳﺒﻮعاﻟﺮاﺑﻊ ﺣﺘﻰ اﻷﺳﺒﻮع اﻟﻌﺎﺷﺮ ﻣﻦ اﻟﻌﺪوي ) ﺪة  ٧أﺳﺎﺑﻴﻊ(.
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 ﻣﺠـﻤﻮﻋﺔ  :٥ﻓـﺌﺮان ﻣـﺼﺎﺑـﺔ و ﺗﻤـﺖ ﻣﻌـﺎﳉﺘﻬـﺎ ﺑﺎﻷﻳـﺰوﺳﻮرﺑـﻴﺪ -٥-أﺣـﺎدي اﻟﻨـﺘﺮات ﻣـﻦ اﻷﺳﺒﻮعاﻟــﺮاﺑﻊ ﺣـﺘﻰ اﻷﺳـﺒـﻮع اﻟـﻌـﺎﺷـﺮ ﻣﻦ اﻟـﻌـﺪوى ) ـﺪة  ٧أﺳـﺎﺑـﻴﻊ( ﺑـﺎﻹﺿـﺎﻓـﺔ إﻟﻰ اﻟـﺒـﺮازﻳـﻜـﻮاﻧـﺘـﻴﻞ ﺑـﻌـﺪ ٦
أﺳﺎﺑﻴﻊ ﻣﻦ اﻟﻌﺪوى.
و ﻗﺪ

ﲢـﺪﻳﺪ ﺗـﺄﺛﻴـﺮ اﻟﻌـﻘﺎرﻳﻦ ﻋﻦ ﻃـﺮﻳﻖ ﺑﻌـﺾ اﻟﺪراﺳـﺎت اﻟﻄـﻔﻴـﻠﻴـﺔ و اﻟﻜـﻴﻤـﻴﺎﺋـﻴﺔ اﳊـﻴﻮﻳﺔ و

اﻟﻨﺴﻴﺠﻴﺔ ا ﺮﺿﻴﺔ.
و ﻗﺪ أدى اﺳـﺘﻌـﻤـﺎل اﻟﺒـﺮازﻳﻜـﻮاﻧﺘـﻴﻞ إﻟﻰ زﻳﺎدة ذات دﻻﻟـﺔ إﺣﺼـﺎﺋـﻴﺔ ﻓﻲ ﻧـﺴﺒـﺔ اﻟﺒـﻮﻳﻀـﺎت ا ﻴـﺘﺔ و
اﻧـﺨـﻔـﺎض ﻋﺪد اﻷورام اﳊـﺒـﻴـﺒـﻴﺔ و ﻟـﻜﻦ ﻟﻢ ﻳـﺆدِ إﻟﻰ اﻧـﺨـﻔﺎض ﻗـﻄـﺮﻫـﺎ ﺑﻴـﻨـﻤـﺎ ﻟﻢ ﻳـﺘﺴـﺒﺐ اﺳـﺘـﺨﺪام
اﻷﻳـﺰوﺳﻮرﺑـﻴﺪ -٥-أﺣﺎدي اﻟـﻨﺘﺮات ﻓﻲ ﺗـﻐﻴـﻴﺮ ﻂ ﻣﺮاﺣﻞ اﻟـﻨﻤـﻮ اﺨﻤﻟﺘﻠـﻔﺔ ﻟـﻠﺒﻮﻳـﻀﺎت و ﻟﻜﻦ أدى إﻟﻰ
ﺗﻘﻠـﻴﻞ اﻻﻟﺘـﻬﺎب و اﻟـﻨﺨـﺮ و ﻗﻄـﺮ اﻷورام اﳊﺒـﻴﺒﺔ و أدى اﺳـﺘﻌـﻤﺎل اﻟـﻌﻘـﺎرﻳﻦ ﻣﻌـﺎً إﻟﻰ زﻳﺎدة ذات دﻻﻟﺔ
إﺣـﺼـﺎﺋـﻴﺔ ﻓﻲ ﻣـﺴـﺘـﻮى أﻛﺴـﻴـﺪ اﻟﻨـﻴـﺘـﺮﻳﻚ ﻓﻲ اﻟـﻜﺒـﺪ و اﻧـﺨـﻔﺎض ﻓﻲ ﻗـﻄـﺮ اﻷورام اﳊـﺒﻴـﺒـﺔ و ﻗﺪ
اﳊﺼﻮل ﻋﻠﻰ أﻓﻀﻞ اﻟﻨﺘﺎﺋﺞ ﻓﻲ اﺠﻤﻟﻤﻮﻋﺔ اﻟﺘﻲ ﺗﻠﻘﺖ اﻟﻌﻘﺎرﻳﻦ ﻣﻌﺎً.
و ﺗُـﺸِ ـﻴـﺮ ﻫـﺬه اﻟـﺪراﺳـﺔ إﻟﻰ إﻣـﻜـﺎﻧـﻴــﺔ اﺳـﺘـﻌـﻤـﺎل اﻷﻳـﺰوﺳـﻮرﺑـﻴـﺪ -٥-أﺣـﺎدي اﻟ ـﻨـﺘـﺮات ﻛـﻌـﻘـﺎر واﻋـﺪ
ﺑﺈﺿـﺎﻓﺘﻪ إﻟﻰ اﻟـﺒﺮازﻳﻜـﻮاﻧﺘـﻴﻞ ﻟﺘـﺤﺴ اﻟـﺘﺄﺛـﻴﺮات ا ـﺮﺿﻴﺔ ﻟـﻠﺒـﻠﻬـﺎرﺳﻴﺎ ﻋـﻠﻰ اﻟﻜـﺒﺪ و ﻳُـﻮﺻﻰ ﺑﺈﺟﺮاء
ا ـﺰﻳـﺪ ﻣﻦ اﻟـﺪراﺳـﺎت ﻻﺳـﺘـﻜـﺸﺎف ﺗـﺄﺛـﻴـﺮات اﻟـﺘـﻨـﺎول ا ﺘـﺰاﻣﻦ ﻟﻸﻳـﺰوﺳـﻮرﺑـﻴـﺪ -٥-أﺣـﺎدي اﻟـﻨـﺘﺮات ﻣﻊ
اﻟﺒﺮازﻳﻜﻮاﻧﺘﻴﻞ ﻓﻲ ا ﺮاﺣﻞ ا ﺘﻘﺪﻣﺔ ﻣﻦ اﻟﺘَﻠَﻴﱡﻒ اﻟﻜﺒﺪي.
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